163 related articles for article (PubMed ID: 37626265)
1. Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas.
Peña M; Montané C; Paviglianiti A; Hurtado L; González S; Carro I; Maluquer C; Domingo-Domenech E; Gonzalez-Barca E; Sureda A; Mussetti A
Bone Marrow Transplant; 2023 Nov; 58(11):1282-1285. PubMed ID: 37626265
[No Abstract] [Full Text] [Related]
2. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
3. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.
Glass B; Hasenkamp J; Wulf G; Dreger P; Pfreundschuh M; Gramatzki M; Silling G; Wilhelm C; Zeis M; Görlitz A; Pfeiffer S; Hilgers R; Truemper L; Schmitz N;
Lancet Oncol; 2014 Jun; 15(7):757-66. PubMed ID: 24827808
[TBL] [Abstract][Full Text] [Related]
4. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy.
Gopal AK; Pagel JM; Rajendran JG; Maloney DG; Appelbaum FR; Sorror ML; Sandmaier BM; Storb R; Press OW
Biol Blood Marrow Transplant; 2006 Jul; 12(7):697-702. PubMed ID: 16785058
[TBL] [Abstract][Full Text] [Related]
5. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.
Satwani P; Jin Z; Martin PL; Bhatia M; Garvin JH; George D; Chaudhury S; Talano J; Morris E; Harrison L; Sosna J; Peterson M; Militano O; Foley S; Kurtzberg J; Cairo MS
Leukemia; 2015 Feb; 29(2):448-55. PubMed ID: 24938649
[TBL] [Abstract][Full Text] [Related]
6. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
Merryman RW; Houot R; Armand P; Jacobson C
Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):345-355.e7. PubMed ID: 31014757
[TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia.
Khouri IF
Hematology Am Soc Hematol Educ Program; 2006; ():390-7. PubMed ID: 17124088
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic transplantation for lymphoma: risk-benefit balance is in the eye of the beholder.
Smith MR
Biol Blood Marrow Transplant; 2014 Jul; 20(7):905-6. PubMed ID: 24831132
[No Abstract] [Full Text] [Related]
10. Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma.
Morris EC; Mackinnon S
Best Pract Res Clin Haematol; 2005 Mar; 18(1):129-42. PubMed ID: 15694189
[TBL] [Abstract][Full Text] [Related]
11. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.
Freytes CO; Zhang MJ; Carreras J; Burns LJ; Gale RP; Isola L; Perales MA; Seftel M; Vose JM; Miller AM; Gibson J; Gross TG; Rowlings PA; Inwards DJ; Pavlovsky S; Martino R; Marks DI; Hale GA; Smith SM; Schouten HC; Slavin S; Klumpp TR; Lazarus HM; van Besien K; Hari PN
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1255-64. PubMed ID: 22198543
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation for patients with resistant high-grade lymphoma: what is the potential of reduced-intensity conditioning?
Dreger P
Ann Oncol; 2002 Sep; 13(9):1507. PubMed ID: 12196382
[No Abstract] [Full Text] [Related]
13. Allogeneic stem cell transplant in non-Hodgkin lymphomas: Still an indication?
Dreger P
Hematol Oncol; 2021 Jun; 39 Suppl 1():100-103. PubMed ID: 34105814
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphoma.
Dogu MH; Çagirgan S; Ocakci S; Kaya AH; Ilkkilic K; Sanli NM; Kahraman S; Eren R; Tekgunduz E; Hacioglu S; Kaynar L; Erkurt MA; Altuntas F
Transfus Apher Sci; 2017 Dec; 56(6):814-818. PubMed ID: 29153347
[TBL] [Abstract][Full Text] [Related]
15. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
Lum LG; Thakur A; Liu Q; Deol A; Al-Kadhimi Z; Ayash L; Abidi MH; Pray C; Tomaszewski EN; Steele PA; Schalk DL; Yano H; Mitchell A; Dufresne M; Uberti JP; Ratanatharathorn V
Biol Blood Marrow Transplant; 2013 Jun; 19(6):925-33. PubMed ID: 23529012
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions.
Ramsdale E; Van Besien K
Leuk Lymphoma; 2011 Aug; 52(8):1415-7. PubMed ID: 21599586
[No Abstract] [Full Text] [Related]
17. Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies.
Novitzky N; Thomas V
Biol Blood Marrow Transplant; 2007 Jan; 13(1):107-15. PubMed ID: 17222759
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.
Pollack SM; Steinberg SM; Odom J; Dean RM; Fowler DH; Bishop MR
Biol Blood Marrow Transplant; 2009 Feb; 15(2):223-30. PubMed ID: 19167682
[TBL] [Abstract][Full Text] [Related]
19. Lymphoma-directed conditioning for aggressive lymphoma.
Sureda A
Lancet Oncol; 2014 Jun; 15(7):678-9. PubMed ID: 24827807
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma.
Gardenswartz A; Mehta B; El-Mallawany NK; van de Ven C; Hochberg J; Flower A; Morris E; Harrison L; Chu Y; Basso J; Gerard P; Islam H; Ayello J; Baxter-Lowe LA; Cairo MS
Leuk Lymphoma; 2023 Jan; 64(1):234-237. PubMed ID: 36260003
[No Abstract] [Full Text] [Related]
[Next] [New Search]
